시장보고서
상품코드
1826867

세계의 항핵항체(ANA) 검사 시장 보고서(2025년)

Antinuclear Antibody Test Global Market Report 2025

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

항핵항체(ANA) 검사 시장 규모는 최근 급속히 확대되고 있습니다. 2024년 15억 4,000만 달러에서 2025년에는 17억 3,000만 달러에 달하고, CAGR 12.6%를 나타낼 전망입니다. 실적기간의 성장은 자가면역질환의 유병률 증가, 조기진단에 대한 의식 증가, 진단기술의 진보, 헬스케어 지출 증가, 노년인구 확대 등으로 인한 것으로 예측됩니다.

항핵항체(ANA) 검사 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 12.4%를 나타내 27억 6,000만 달러로 성장할 전망입니다. 예측기간의 성장은 자가면역질환의 이환율 상승, 진단 도구의 기술적 진보, 맞춤형 의료에 대한 주목 증가, 개발도상지역에서의 헬스케어 인프라 증가, 질환의 조기 발견 및 관리에 대한 수요 증가에 기인하고 있습니다. 예측기간의 주요 동향으로는 진단에 있어서의 인공지능의 통합, POC(Point-of-Care) 검사 기기의 개발, 멀티플렉스 검사 기술의 채용, 데이터 분석에 있어서의 머신러닝의 이용, 자동화 및 고스루풋 검사 시스템의 개선 등을 들 수 있습니다.

항핵항체(ANA) 검사는 체내 세포를 표적으로 하는 자가항체를 검출하는 혈액검사이며, 루푸스, 류마티스 관절염 및 기타 관련 질환과 같은 자가면역 질환의 중요한 진단 도구가 되고 있습니다.

ANA 검사의 주요 제품 유형은 분석 키트, 시약 키트, 소프트웨어 및 서비스를 포함합니다. 분석 키트는 환자 시료에서 항핵 항체를 확인하기 위해 고안된 시약 및 프로토콜의 포장 세트입니다. 이 검사는 류마티스 관절염, 전신성 홍반성 루푸스 및 기타자가 면역 질환의 진단과 같은 응용을 위해 면역 형광 분석, 멀티플렉스 분석, ELISA 등과 같은 다양한 기술을 이용합니다. 류마티스 관절염, 전신성 홍반성 루푸스 및 기타자가 면역 질환의 진단과 같은 용도로 병원, 임상 실험실, 의사 실험실 등 다양한 최종 사용자에게 널리 사용됩니다.

2025년 봄 미국 관세의 급상승과 이에 따른 무역 마찰은 의료 분야, 특히 필수적인 의료기기, 진단 장비 및 의약품 공급에 큰 영향을 미쳤습니다. 병원과 건강 관리 제공업체는 수입되는 수술 기구, 영상 진단 시스템, 주사기 및 카테터와 같은 소모품의 비용 상승에 시달리고 있으며, 그 대부분은 국내 대체품이 제한되어 있습니다. 이러한 비용 상승이 의료 예산을 압박하기 때문에 일부 의료기관은 장비 업그레이드를 늦추거나 비용 증가를 환자에게 전가하고 있습니다. 게다가 원료와 부품에 대한 관세는 중요한 의약품과 의료기기의 제조에 지장을 주고 공급망의 지연으로 이어지고 있습니다. 이에 비해 업계는 다양한 조달 전략을 채택하고 가능한 한 현지 생산을 확대하고 중요한 의료 제품의 관세 면제를 수행하고 있습니다.

이 조사 보고서는 항핵항체(ANA) 검사 업계 세계 시장 규모, 지역 점유율, 항핵항체(ANA) 검사 시장 점유율을 가진 경쟁업체, 상세한 항핵항체(ANA) 검사 시장 부문, 시장 동향과 비즈니스 기회, 항핵항체(ANA) 검사 업계에서 성공하기 위해 필요한 데이터 등 항핵항체(ANA) 검사 시장 통계를 제공하는 The Business Research Company의 신간 보고서 시리즈 중 하나입니다. 이 항핵항체(ANA) 검사 시장 조사 보고서는 업계의 현재 및 미래 시나리오를 자세히 분석하고 필요한 모든 것을 완벽한 관점에서 제공합니다.

향후 5년간의 성장률 12.4%라고 하는 예측은 전회 예측으로부터 0.2%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세장벽은 독일과 일본에서 공급되는 면역형광 항핵항체(ANA) 검사 키트와 자동효소결합 면역흡착 측정법(ELISA) 플랫폼의 비용을 상승시키고, 자가면역질환의 진단을 지연시키고, 류마티스 검사실 지출을 증가시킴으로써 미국을 저해할 것으로 예측됩니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

자가면역 질환의 유병률 증가는 항핵항체(ANA) 검사 시장 확대를 촉진할 것으로 예측됩니다. 자가 면역 질환은 면역계가 실수로 신체의 건강한 세포와 조직을 공격함으로써 발생합니다. 이러한 질병의 발생률 증가는 유전적 소인, 환경적 유인, 호르몬 변화, 다이어트 및 스트레스와 같은 라이프 스타일 요소와 같은 요인에 의해 영향을 받습니다. 항핵항체(ANA) 검사는 몸 자체의 세포나 조직을 표적으로 하는 항체를 확인함으로써 자가면역질환의 조기 발견에 중요한 역할을 하고 있습니다. 예를 들어, 2024년 6월 호주 정부 기관인 호주 보건복지연구소가 발표한 보고서에 따르면, 2021-2022년 류마티스 관절염에 의한 입원 환자 수는 1만 명에 달했고, 전년 8,000명에서 25% 증가했습니다. 이는 인구 10만 명당 39명의 입원률에 해당합니다. 그 결과, 자가면역질환의 유병률 상승이 항핵항체(ANA) 검사 시장 성장을 뒷받침하고 있습니다.

항핵항체(ANA) 검사 시장 주요 기업은 ANA 검사의 정확성, 효율성 및 자동화를 향상시키기 위해 디지털 면역 형광 시스템과 같은 첨단 진단 기술의 개척에 주력하고 있습니다. 디지털 면역형광 시스템은 고해상도 이미징과 AI를 사용하여 면역형광 분석을 자동화하여 자가면역 질환 진단의 정확성을 향상시킵니다. 예를 들어, 미국에 기반을 둔 진단 솔루션 제공업체인 ZEUS Scientific Inc.는 2022년 3월 ZEUS dIFine IFA Imaging and Pattern Recognition System의 FDA 인가를 취득했습니다. 이 승인은 ZEUS의 ANA HEp-2 간접 형광 항체(IFA) 분석을 강화하는 dIFine 플랫폼의 HEp-2 ANA IFA 검사 시스템에 적용됩니다. 클리어런스에는 양성 및 음성을 결정하고 8개의 일반적인 ANA HEp-2 염색 패턴을 인식하는 기능이 포함됩니다. 게다가 이 시스템에는 패턴 아틀라스가 내장되어 있어 ICAP 명명법에 따른 ZEUS 독자적인 이미지와 나란히 비교할 수 있습니다.

2022년 6월 스위스의 진단 회사 Quotient Limited는 자가면역 질환 진단을 개선하기 위해 Theradiag와 제휴했습니다. 이 제휴는 Theradiag의 시약과 Quotient의 MosaiQ 플랫폼을 통합하여 보다 신속하고 정확한 진단 및 치료 선택을 가능하게 하는 다중화 마이크로어레이의 개발을 목표로 하고 있습니다. Theradiag사는 프랑스에 본사를 두는 항핵항체(ANA) 검사를 제공하는 기업입니다.

항핵항체(ANA) 검사 시장은 임상검사 서비스, 특수검사 서비스, 질병활동성 모니터링, 전신성 홍반성 루푸스 스크리닝 등의 서비스를 제공하는 기업이 얻는 수익으로 구성되어 있습니다. 시장 가치에는 서비스 제공업체가 판매하거나 서비스 제공에 포함된 관련 상품의 가치도 포함됩니다. 항핵항체(ANA) 검사 시장에는 진단 장비 및 기구, 검사 키트, 웨스턴 블롯 키트, 루미넥스 멀티플렉스 분석의 판매도 포함됩니다. 이 시장의 가치는 "Factory Gate"가치, 즉 다른 기업(다운스트림 제조업자, 도매업체, 유통업체, 소매업체 포함)이든 직접 최종 고객이든, 상품 제조업체 또는 제작자가 판매한 상품의 가치입니다. 이 시장에서 상품의 가치에는 상품 제작자에 의해 판매되는 관련 서비스도 포함됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

  • 세계의 항핵항체(ANA) 검사 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
  • 최종 이용 산업의 분석
  • 세계의 항핵항체(ANA) 검사 시장 : 성장률 분석
  • 세계의 항핵항체(ANA) 검사 시장 실적 : 규모와 성장(2019-2024년)
  • 세계의 항핵항체(ANA) 검사 시장 예측 : 규모와 성장(2024-2029년, 2034년)
  • 세계의 항핵항체(ANA) 검사 : 전체 시장 규모(TAM)

제6장 시장 세분화

  • 세계의 항핵항체(ANA) 검사 시장 : 제품별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
  • 분석 키트
  • 시약 키트
  • 소프트웨어 및 서비스
  • 세계의 항핵항체(ANA) 검사 시장 : 기술별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
  • 면역형광 분석법
  • 다중 분석법
  • ELISA
  • 세계의 항핵항체(ANA) 검사 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
  • 류마티스 관절염
  • 전신성 홍반성 루푸스
  • 기타 용도
  • 세계의 항핵항체(ANA) 검사 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
  • 병원
  • 임상
  • 의사 실험실
  • 세계의 항핵항체(ANA) 검사 시장 : 분석 키트 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
  • 효소결합 면역흡착 분석법(ELISA) 키트
  • 면역형광 분석법(IFA) 키트
  • 웨스턴 블롯 검사 키트
  • 세계의 항핵항체(ANA) 검사 시장 : 시약 키트 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
  • 항원 시약
  • 접합 항체
  • 검출 시약
  • 세계의 항핵항체(ANA) 검사 시장 : 소프트웨어 및 서비스 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
  • 데이터 관리 소프트웨어
  • 실험실 정보 관리 시스템(LIMS)
  • 기술 지원 및 컨설팅 서비스

제7장 지역별/국가별 분석

  • 세계의 항핵항체(ANA) 검사 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
  • 세계의 항핵항체(ANA) 검사 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

  • 항핵항체(ANA) 검사 시장 : 경쟁 구도
  • 항핵항체(ANA) 검사 시장 : 기업 프로파일
    • Hoffmann-La Roche Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
    • Thermo Fisher Scientific Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
    • Abbott Laboratories : 개요, 제품 및 서비스, 전략 및 재무 분석
    • Becton Dickinson and Company : 개요, 제품 및 서비스, 전략 및 재무 분석
    • LabCorp : 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

  • Quest Diagnostics Incorporated
  • Grifols SA
  • PerkinElmer Inc.
  • Bio-Rad Laboratories Inc.
  • Werfen SA
  • DiaSorin SpA
  • EUROIMMUN AG
  • Abcam plc
  • Trinity Biotech plc
  • Zeus Scientific Inc.
  • ERBA Diagnostics Inc.
  • Quidel Corporation
  • Antibodies Incorporated
  • Immuno Concepts Inc.
  • Inova Diagnostics

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

  • 항핵항체(ANA) 검사 시장(2029년) : 새로운 기회를 제공하는 국가
  • 항핵항체(ANA) 검사 시장(2029년) : 새로운 기회를 제공하는 부문
  • 항핵항체(ANA) 검사 시장(2029년) : 성장 전략
    • 시장 동향에 기초한 전략
    • 경쟁 전략

제36장 부록

KTH 25.10.17

An antinuclear antibody (ANA) test is a blood test that detects autoantibodies targeting the body's own cells, serving as a key diagnostic tool for autoimmune diseases such as lupus, rheumatoid arthritis, and other related disorders.

The main product types in ANA testing include assay kits, reagent kits, and software and services. Assay kits are pre-packaged sets of reagents and protocols designed to identify antinuclear antibodies in patient samples. The test utilizes various technologies, including immunofluorescence assays, multiplex assays, and ELISA, for applications such as diagnosing rheumatoid arthritis, systemic lupus erythematosus, and other autoimmune conditions. It is widely used across different end users, including hospitals, clinical laboratories, and physician laboratories.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The antinuclear antibody test market research report is one of a series of new reports from The Business Research Company that provides antinuclear antibody test market statistics, including antinuclear antibody test industry global market size, regional shares, competitors with an antinuclear antibody test market share, detailed antinuclear antibody test market segments, market trends and opportunities, and any further data you may need to thrive in the antinuclear antibody test industry. This antinuclear antibody test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antinuclear antibody test market size has grown rapidly in recent years. It will grow from $1.54 billion in 2024 to $1.73 billion in 2025 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to the increasing prevalence of autoimmune diseases, rising awareness about early diagnosis, advancements in diagnostic technologies, growing healthcare expenditure, and expanding geriatric population.

The antinuclear antibody test market size is expected to see rapid growth in the next few years. It will grow to $2.76 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to the rising incidence of autoimmune disorders, technological advancements in diagnostic tools, a growing focus on personalized medicine, increasing healthcare infrastructure in developing regions, and rising demand for early disease detection and management. Major trends in the forecast period include the integration of artificial intelligence in diagnostics, the development of point-of-care testing devices, the adoption of multiplex testing technologies, the use of machine learning for data analysis, and improvements in automation and high-throughput testing systems.

The forecast of 12.4% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of immunofluorescence Antinuclear Antibody(ANA) test kits and automated enzyme-linked immunosorbent assay(ELISA) platforms sourced from Germany and Japan, thereby delaying autoimmune disease diagnosis and elevating rheumatology lab expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of autoimmune diseases is expected to drive the expansion of the antinuclear antibody test market. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells and tissues. The growing incidence of these conditions is influenced by factors such as genetic predisposition, environmental triggers, hormonal changes, and lifestyle elements such as diet and stress. The antinuclear antibody test plays a crucial role in the early detection of autoimmune diseases by identifying antibodies that target the body's own cells and tissues. For example, in June 2024, a report published by the Australian Institute of Health and Welfare, an Australian governmental organization, indicated that hospitalizations for rheumatoid arthritis reached 10,000 in 2021-22, reflecting a 25% increase from the previous year's 8,000 cases. This corresponds to a hospitalization rate of 39 per 100,000 people. As a result, the rising prevalence of autoimmune diseases is fueling the growth of the antinuclear antibody test market.

Leading companies in the antinuclear antibody test market are focusing on developing advanced diagnostic technologies, such as digital immunofluorescence systems, to improve the accuracy, efficiency, and automation of ANA testing. Digital immunofluorescence systems automate immunofluorescence assay analysis using high-resolution imaging and AI, enhancing precision in autoimmune disease diagnostics. For instance, in March 2022, ZEUS Scientific Inc., a US-based provider of diagnostic solutions, received FDA clearance for its ZEUS dIFine IFA Imaging and Pattern Recognition System. This approval applies to the HEp-2 ANA IFA test system on the dIFine platform, which enhances ZEUS' ANA HEp-2 indirect fluorescent antibody (IFA) assay. The clearance includes features for determining positive and negative results and recognizing eight common ANA HEp-2 staining patterns. Additionally, the system incorporates a built-in pattern atlas that serves as a reference and training tool, enabling side-by-side image comparisons with ZEUS' proprietary images aligned with ICAP nomenclature.

In June 2022, Quotient Limited, a Switzerland-based diagnostics company, partnered with Theradiag to improve autoimmune disease diagnostics. This collaboration integrates Theradiag's reagents with Quotient's MosaiQ platform, aiming to develop multiplexed microarrays that enable faster, more accurate diagnosis and treatment selection. Theradiag is a France-based company that provides antinuclear antibody (ANA) tests.

Major players in the antinuclear antibody test market are Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Becton Dickinson and Company, LabCorp, Quest Diagnostics Incorporated, Grifols SA, PerkinElmer Inc., Bio-Rad Laboratories Inc., Werfen SA, DiaSorin SpA, EUROIMMUN AG, Abcam plc, Trinity Biotech plc, Zeus Scientific Inc., ERBA Diagnostics Inc., Quidel Corporation, Antibodies Incorporated, Immuno Concepts Inc., Inova Diagnostics.

North America was the largest region in the antinuclear antibody test market in 2024. Asia-pacific is expected to be the fastest-growing region in the forecast period. The regions covered in antinuclear antibody test report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the antinuclear antibody test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antinuclear antibody test market consists of revenues earned by entities by providing services such as laboratory testing services, specialized testing services, monitoring disease activity, and screening for systemic lupus erythematosus. The market value includes the value of related goods sold by the service provider or included within the service offering. The antinuclear antibody test market also includes sales of diagnostic equipment and instruments, testing kits, western blot kits and luminex multiplex assays. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antinuclear Antibody Test Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antinuclear antibody test market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antinuclear antibody test ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The antinuclear antibody test market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Assay Kits; Reagent Kits; Software And Services
  • 2) By Technology: Immunofluorescence Assay; Multiplex Assay; ELISA
  • 3) By Application: Rheumatoid Arthritis; Systemic Lupus Erythematosus; Other Applications
  • 4) By End-User: Hospitals; Clinical; Physician Laboratories
  • Subsegments:
  • 1) By Assay Kits: Enzyme-Linked Immunosorbent Assay (ELISA) Kits; Immunofluorescence Assay (IFA) Kits; Western Blot Assay Kits
  • 2) By Reagent Kits: Antigen Reagents; Conjugated Antibodies; Detection Reagents
  • 3) By Software And Services: Data Management Software; Laboratory Information Management Systems (LIMS); Technical Support And Consulting Services
  • Companies Mentioned: Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Abbott Laboratories; Becton Dickinson and Company; LabCorp; Quest Diagnostics Incorporated; Grifols SA; PerkinElmer Inc.; Bio-Rad Laboratories Inc.; Werfen SA; DiaSorin SpA; EUROIMMUN AG; Abcam plc; Trinity Biotech plc; Zeus Scientific Inc.; ERBA Diagnostics Inc.; Quidel Corporation; Antibodies Incorporated; Immuno Concepts Inc.; Inova Diagnostics
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Antinuclear Antibody Test Market Characteristics

3. Antinuclear Antibody Test Market Trends And Strategies

4. Antinuclear Antibody Test Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Antinuclear Antibody Test Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Antinuclear Antibody Test PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Antinuclear Antibody Test Market Growth Rate Analysis
  • 5.4. Global Antinuclear Antibody Test Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Antinuclear Antibody Test Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Antinuclear Antibody Test Total Addressable Market (TAM)

6. Antinuclear Antibody Test Market Segmentation

  • 6.1. Global Antinuclear Antibody Test Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Assay Kits
  • Reagent Kits
  • Software And Services
  • 6.2. Global Antinuclear Antibody Test Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Immunofluorescence Assay
  • Multiplex Assay
  • ELISA
  • 6.3. Global Antinuclear Antibody Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus
  • Other Applications
  • 6.4. Global Antinuclear Antibody Test Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Clinical
  • Physician Laboratories
  • 6.5. Global Antinuclear Antibody Test Market, Sub-Segmentation Of Assay Kits, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Enzyme-Linked Immunosorbent Assay (ELISA) Kits
  • Immunofluorescence Assay (IFA) Kits
  • Western Blot Assay Kits
  • 6.6. Global Antinuclear Antibody Test Market, Sub-Segmentation Of Reagent Kits, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Antigen Reagents
  • Conjugated Antibodies
  • Detection Reagents
  • 6.7. Global Antinuclear Antibody Test Market, Sub-Segmentation Of Software And Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Data Management Software
  • Laboratory Information Management Systems (LIMS)
  • Technical Support And Consulting Services

7. Antinuclear Antibody Test Market Regional And Country Analysis

  • 7.1. Global Antinuclear Antibody Test Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Antinuclear Antibody Test Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Antinuclear Antibody Test Market

  • 8.1. Asia-Pacific Antinuclear Antibody Test Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Antinuclear Antibody Test Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Antinuclear Antibody Test Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Antinuclear Antibody Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Antinuclear Antibody Test Market

  • 9.1. China Antinuclear Antibody Test Market Overview
  • 9.2. China Antinuclear Antibody Test Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Antinuclear Antibody Test Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Antinuclear Antibody Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Antinuclear Antibody Test Market

  • 10.1. India Antinuclear Antibody Test Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Antinuclear Antibody Test Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Antinuclear Antibody Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Antinuclear Antibody Test Market

  • 11.1. Japan Antinuclear Antibody Test Market Overview
  • 11.2. Japan Antinuclear Antibody Test Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Antinuclear Antibody Test Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Antinuclear Antibody Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Antinuclear Antibody Test Market

  • 12.1. Australia Antinuclear Antibody Test Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Antinuclear Antibody Test Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Antinuclear Antibody Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Antinuclear Antibody Test Market

  • 13.1. Indonesia Antinuclear Antibody Test Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Antinuclear Antibody Test Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Antinuclear Antibody Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Antinuclear Antibody Test Market

  • 14.1. South Korea Antinuclear Antibody Test Market Overview
  • 14.2. South Korea Antinuclear Antibody Test Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Antinuclear Antibody Test Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Antinuclear Antibody Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Antinuclear Antibody Test Market

  • 15.1. Western Europe Antinuclear Antibody Test Market Overview
  • 15.2. Western Europe Antinuclear Antibody Test Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Antinuclear Antibody Test Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Antinuclear Antibody Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Antinuclear Antibody Test Market

  • 16.1. UK Antinuclear Antibody Test Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Antinuclear Antibody Test Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Antinuclear Antibody Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Antinuclear Antibody Test Market

  • 17.1. Germany Antinuclear Antibody Test Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Antinuclear Antibody Test Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Antinuclear Antibody Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Antinuclear Antibody Test Market

  • 18.1. France Antinuclear Antibody Test Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Antinuclear Antibody Test Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Antinuclear Antibody Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Antinuclear Antibody Test Market

  • 19.1. Italy Antinuclear Antibody Test Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Antinuclear Antibody Test Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Antinuclear Antibody Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Antinuclear Antibody Test Market

  • 20.1. Spain Antinuclear Antibody Test Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Antinuclear Antibody Test Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Antinuclear Antibody Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Antinuclear Antibody Test Market

  • 21.1. Eastern Europe Antinuclear Antibody Test Market Overview
  • 21.2. Eastern Europe Antinuclear Antibody Test Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Antinuclear Antibody Test Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Antinuclear Antibody Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Antinuclear Antibody Test Market

  • 22.1. Russia Antinuclear Antibody Test Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Antinuclear Antibody Test Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Antinuclear Antibody Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Antinuclear Antibody Test Market

  • 23.1. North America Antinuclear Antibody Test Market Overview
  • 23.2. North America Antinuclear Antibody Test Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Antinuclear Antibody Test Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Antinuclear Antibody Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Antinuclear Antibody Test Market

  • 24.1. USA Antinuclear Antibody Test Market Overview
  • 24.2. USA Antinuclear Antibody Test Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Antinuclear Antibody Test Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Antinuclear Antibody Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Antinuclear Antibody Test Market

  • 25.1. Canada Antinuclear Antibody Test Market Overview
  • 25.2. Canada Antinuclear Antibody Test Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Antinuclear Antibody Test Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Antinuclear Antibody Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Antinuclear Antibody Test Market

  • 26.1. South America Antinuclear Antibody Test Market Overview
  • 26.2. South America Antinuclear Antibody Test Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Antinuclear Antibody Test Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Antinuclear Antibody Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Antinuclear Antibody Test Market

  • 27.1. Brazil Antinuclear Antibody Test Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Antinuclear Antibody Test Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Antinuclear Antibody Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Antinuclear Antibody Test Market

  • 28.1. Middle East Antinuclear Antibody Test Market Overview
  • 28.2. Middle East Antinuclear Antibody Test Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Antinuclear Antibody Test Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Antinuclear Antibody Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Antinuclear Antibody Test Market

  • 29.1. Africa Antinuclear Antibody Test Market Overview
  • 29.2. Africa Antinuclear Antibody Test Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Antinuclear Antibody Test Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Antinuclear Antibody Test Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Antinuclear Antibody Test Market Competitive Landscape And Company Profiles

  • 30.1. Antinuclear Antibody Test Market Competitive Landscape
  • 30.2. Antinuclear Antibody Test Market Company Profiles
    • 30.2.1. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Becton Dickinson and Company Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. LabCorp Overview, Products and Services, Strategy and Financial Analysis

31. Antinuclear Antibody Test Market Other Major And Innovative Companies

  • 31.1. Quest Diagnostics Incorporated
  • 31.2. Grifols SA
  • 31.3. PerkinElmer Inc.
  • 31.4. Bio-Rad Laboratories Inc.
  • 31.5. Werfen SA
  • 31.6. DiaSorin SpA
  • 31.7. EUROIMMUN AG
  • 31.8. Abcam plc
  • 31.9. Trinity Biotech plc
  • 31.10. Zeus Scientific Inc.
  • 31.11. ERBA Diagnostics Inc.
  • 31.12. Quidel Corporation
  • 31.13. Antibodies Incorporated
  • 31.14. Immuno Concepts Inc.
  • 31.15. Inova Diagnostics

32. Global Antinuclear Antibody Test Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antinuclear Antibody Test Market

34. Recent Developments In The Antinuclear Antibody Test Market

35. Antinuclear Antibody Test Market High Potential Countries, Segments and Strategies

  • 35.1 Antinuclear Antibody Test Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Antinuclear Antibody Test Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Antinuclear Antibody Test Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제